9 recruiting, 3 unknown, 2 completed, 2 terminated. 10 Phase 2, 2 Early Phase 1, 2 Not applicable, 2 Phase 3.
Follow this condition Literature Review of Laryngeal Squamous Cell Carcinoma trials Research Report on Laryngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intralesional Chemotherapy (IC): Cisplatin + Epinephrine Cisplatin, Epinephrine injection, Laryngeal Biopsy - Laryngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Miami | 20 | 2026-12-01 | 2026-08-26 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer Compartmentalized Postoperative Radiotherapy - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Olgun Elicin | 50 | 2026-01-15 | 2026-08-27 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| Decisional Regret in Open Partial Horizontal Laryngectomy Laryngeal Squamous Cell Carcinoma | Unknown | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 100 | 2024-05-01 | 2025-02-03 | |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] KEYTRUDA® - Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | University of Leipzig | 140 | 2024-04-17 | 2024-09-20 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. Sentinel lymph node biopsy guided selective elective neck irradiation, Standard elective neck irradiation - Laryngeal Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma | Phase 3 | Recruiting | Radboud University Medical Center | 242 | 2023-12-06 | 2025-11-24 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy. Immunohistochemistry - Laryngeal Squamous Cell Carcinoma | Unknown | Assiut University | 52 | 2023-05-01 | 2023-04-27 | |
| IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate Laryngeal Squamous Cell Carcinoma | Unknown | Sohag University | 70 | 2022-06-01 | 2022-04-01 | |
| Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer Carboplatin, Cisplatin, Docetaxel - Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 28 | 2019-08-07 | 2026-03-09 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 189 | 2016-11-23 | 2026-09-14 |
| Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement - Current Smoker, Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Terminated | Wake Forest University Health Sciences | 9 | 2016-01-01 | 2023-03-22 |
| A Trial of Perioperative Immune Enhancing Feed in Patients Undergoing Surgery for Head and Neck Cancer IMPACT, An iso-caloric, iso-nitrogenous control feed - Squamous Cell Carcinoma of Mouth, Squamous Cell Carcinoma of Oropharynx | Not applicable | Completed | Terrence Jones | 76 | 2003-11-01 | 2020-08-07 |
Squamous Cell Carcinoma of Head and Neck (18) · Laryngeal Neoplasms (9) · Carcinoma (8) · Hypopharyngeal Neoplasms (6) · Mouth Neoplasms (6) · Nasopharyngeal Carcinoma (4) · Oropharyngeal Neoplasms (4) · Head and Neck Neoplasms (3) · Anus Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Infections (1) · Lymphoid Interstitial Pneumonia (1) · Melanoma (1)
Neoplasms (18) · Neoplasms by Histologic Type (18) · Neoplasms by Site (18) · Neoplasms, Glandular and Epithelial (18) · Carcinoma, Squamous Cell (17) · Head and Neck Neoplasms (15) · Carcinoma (10) · Otorhinolaryngologic Diseases (10) · Otorhinolaryngologic Neoplasms (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Laryngeal Diseases (9) · Pharyngeal Diseases (8) · Pharyngeal Neoplasms (8) · Stomatognathic Diseases (8)
Cisplatin (5) · Radiotherapy, Intensity-Modulated (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Magnetic Resonance Spectroscopy (4) · Platinum (4) · Specimen Handling (3) · Carboplatin (2) · Radiotherapy, Image-Guided (2) · pembrolizumab (2) · (225)Ac-DOTA-c(RGDyK) (1) · Biopsy (1) · Bupropion (1) · Cetuximab (1) · Disulfides (1) · Docetaxel (1)
ECOG-ACRIN Cancer Research Group (2) · Emory University (2) · National Cancer Institute (NCI) (2) · Assiut University (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · M.D. Anderson Cancer Center (1) · MacroGenics (1) · NRG Oncology (1) · Olgun Elicin (1) · Radboud University Medical Center (1) · Sohag University (1) · Terrence Jones (1) · University of Leipzig (1) · University of Miami (1) · Wake Forest University Health Sciences (1)
United States (10) · Italy (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · Switzerland (1)
Amol M Takalkar, MD, MS, MBA, FACNM (1) · Asmaa AM Abd El-latif (1) · David M Brizel (1) · David Rosow, MD (1) · Heath D Skinner (1) · Liudmila Schafer, M.D. (1) · Loren K Mell (1) · Matin Imanguli (1) · Matteo Fermi, MD (1) · Mercedes Porosnicu (1) · Nicole C Schmitt, MD, FACS (1) · Renata Ferrarotto (1) · Robert Ferris (1) · Terence M Jones, MD (1) · Timo Nannen (1)
PMID 33605440, PMID 39239277, PMID 39551064
P30CA138292 (2), U10CA180820 (2), K24DC022077 (1), P30CA012197 (1), U10CA180868 (1), UG1CA189867 (1), UM1CA186691 (1)